Related Experiment Video
Updated: Dec 13, 2025
04:28
Lung Tumor Cell Recruitment Assay
Published on: February 26, 2019
5.8K
The CCL20-CCR6 Axis in Cancer Progression
Suguru Kadomoto1, Kouji Izumi1, Atsushi Mizokami1
1Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa 920-8641, Ishikawa, Japan.
International Journal of Molecular Sciences
|July 26, 2020
Summary
The chemokine (C-C motif) ligand 20 (CCL20)-chemokine (C-C) receptor 6 (CCR6) axis is implicated in cancer progression. Targeting this axis offers potential therapeutic strategies for various cancers.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Chemokines mediate leukocyte migration in inflammation.
- Chemokine (C-C motif) ligand 20 (CCL20) and its receptor C-C chemokine receptor 6 (CCR6) are key players in immune responses.
- The CCL20-CCR6 axis is known to be involved in inflammatory and infectious diseases.
Purpose of the Study:
- To review the role of the CCL20-CCR6 axis in cancer progression.
- To explore the potential of the CCL20-CCR6 axis as a therapeutic target in cancer.
Main Methods:
- Literature review of studies investigating the CCL20-CCR6 axis in cancer.
- Analysis of the mechanisms by which CCL20-CCR6 influences cancer cell behavior and the tumor microenvironment.
Main Results:
- The CCL20-CCR6 axis is associated with multiple cancers, including hepatocellular, colorectal, breast, pancreatic, cervical, and kidney cancers.
- This axis promotes cancer progression by enhancing cancer cell migration and proliferation.
- It also contributes to tumor microenvironment remodeling via immune cell modulation.
Conclusions:
- The CCL20-CCR6 axis plays a significant role in the progression of various cancers.
- Targeting the CCL20-CCR6 axis presents a promising therapeutic strategy for cancer treatment.
Related Concept Videos
02:07Tumor Progression
7.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
02:53Adaptive Mechanisms in Cancer Cells
6.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.7K
01:35Cancer Cell Migration through Invadopodia
3.0K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.0K
02:30Metastasis
6.2K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.2K
03:03mTOR Signaling and Cancer Progression
4.5K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.5K
02:40Cancer Stem Cells and Tumor Maintenance
5.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.7K